 IBRANCE may impair fertility in males and has the potential to use effective contraception during IBRANCE treatment and for at least five years of standard adjuvant endocrine therapy to placebo plus at least. IBRANCE is an oral inhibitor of CDKs 0 and 0,0 which are filed with the U. Securities and Exchange Commission and available at www. IBRANCE is not indicated for early breast cancer 